Targazyme

Targazyme Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company employs 7 individuals and generates an annual revenue of $2.5 million. Targazyme develops novel enzyme-based platform technologies and products aimed at improving clinical outcomes for various medical fields. Their focus areas include cell therapy, immunotherapy for autoimmune diseases and cancer, stem cell transplantation, gene therapy, and regenerative medicine. The company's key products include TZ101 and TZ102, clinical-grade fucosyltransferase enzymes and small molecule products designed to be used at the point-of-care to treat therapeutic cells before patient infusion. Targazyme boasts a strong intellectual property portfolio, holding worldwide patents and receiving multiple FDA orphan drug designations for their products. They have conducted extensive research, culminating in an open investigational new drug application (IND) with ongoing clinical studies and a Phase 3 Special Protocol Assessment (SPA) with the FDA. The company's innovative fucosylation technology has also garnered recognition through numerous awards from prestigious institutions such as the NIH, NCI, US Treasury, CPRIT, ETF, OCAST, JDRF, and Leukemia & Lymphoma Society. To learn more about Targazyme and their groundbreaking work, visit their website at http://www.targazyme.com.